IGM Biosciences, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Cash flows from operating activities:
Net Income Loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Stock-based compensation expense
Purchase of net discounts on marketable securities
Net accretion of discounts on marketable securities
Non-cash lease expense
Other
Changes in assets and liabilities:
Prepaid expenses and other current assets
Other non-current assets
Income tax receivable
Accounts payable
Accrued liabilities
Lease liabilities, net
Deferred revenue
Other non-current liabilities
Net cash used in operating activities
Cash flows from investing activities:
Purchase of property, plant and equipment
Purchases of marketable securities
Proceeds from maturities and sales of marketable securities
Sales of investments
Proceeds from sales of marketable securities
Proceeds from sales of property, plant and equipment
Net cash provided by (used in) investing activities

Cash flows from financing activities:
Proceeds from exercise of stock options
Proceeds from purchases under the employee stock purchase plan
Payment of issuance costs for public offerings
IPO
Total payment of issuance costs for public offerings
Proceeds from issuance of common stock in public offering and private placement, net of offering costs
Proceeds from issuance of common stock in public offerings, net of offering costs
Proceeds from exercise of stock options and purchases under the employee stock purchase plan
Payment of deferred offering costs
Payment of employee taxes and exercise costs for shares withheld
Net cash provided by financing activities

Net decrease in cash, cash equivalents and restricted cash
Cash, cash equivalents, and restricted cash Beginning of period
Cash, cash equivalents, and restricted cash, End of period
Cash and cash equivalents
Restricted cash
Cash, cash equivalents, and restricted cash
Supplemental cash flow data:
Cash paid for income taxes
Supplemental disclosure of non-cash investing and financing activities:
Right-of-use assets recognized in exchange for lease obligations
Unpaid amounts related to purchase of property, plant and equipment
Unpaid amounts related to offering costs for public offerings

Comments